Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CSL Limited stock logo
CSLLY
CSL
$79.57
-1.5%
$77.98
$70.22
$109.00
$77.06B0.7994,941 shs51,638 shs
EssilorLuxottica Société anonyme stock logo
ESLOY
EssilorLuxottica Société anonyme
$140.61
-2.2%
$141.93
$103.41
$155.46
$128.66B1.0837,489 shs41,007 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$108.44
-0.6%
$105.33
$62.07
$119.96
$134.89B0.267.72 million shs4.59 million shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$445.10
-0.2%
$473.44
$377.85
$519.88
$114.30B0.511.42 million shs1.21 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CSL Limited stock logo
CSLLY
CSL
+1.29%+3.13%+3.30%-3.07%-13.58%
EssilorLuxottica Société anonyme stock logo
ESLOY
EssilorLuxottica Société anonyme
+1.02%-2.28%-0.75%-2.50%+27.56%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+1.60%-0.02%+5.74%-1.24%+66.09%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
+2.29%-0.26%-9.69%-6.91%-2.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CSL Limited stock logo
CSLLY
CSL
0.8553 of 5 stars
0.03.01.70.01.30.01.3
EssilorLuxottica Société anonyme stock logo
ESLOY
EssilorLuxottica Société anonyme
1.6979 of 5 stars
0.05.01.70.02.20.01.3
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.6824 of 5 stars
2.43.04.24.13.02.51.9
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
4.4044 of 5 stars
3.33.00.03.34.22.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CSL Limited stock logo
CSLLY
CSL
4.00
Strong BuyN/AN/A
EssilorLuxottica Société anonyme stock logo
ESLOY
EssilorLuxottica Société anonyme
2.00
HoldN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.78
Moderate Buy$110.551.94% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.57
Moderate Buy$515.0415.71% Upside

Current Analyst Ratings Breakdown

Latest ESLOY, CSLLY, VRTX, and GILD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/23/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/21/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/7/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Peer Perform
5/6/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/6/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/6/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/6/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$450.00 ➝ $442.00
5/6/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$420.00 ➝ $423.00
5/6/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$462.00 ➝ $464.00
5/6/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$512.00 ➝ $515.00
5/6/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$535.00 ➝ $535.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CSL Limited stock logo
CSLLY
CSL
$14.80B5.21$3.83 per share20.80$20.07 per share3.96
EssilorLuxottica Société anonyme stock logo
ESLOY
EssilorLuxottica Société anonyme
$28.69B4.48$6.45 per share21.80$46.37 per share3.03
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$28.74B4.69$8.57 per share12.66$15.44 per share7.02
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$11.10B10.30N/AN/A$63.90 per share6.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CSL Limited stock logo
CSLLY
CSL
$2.64BN/A0.0019.451.59N/AN/AN/AN/A
EssilorLuxottica Société anonyme stock logo
ESLOY
EssilorLuxottica Société anonyme
$2.55BN/A0.0031.32N/AN/AN/AN/A7/28/2025 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$480M$4.75293.0813.370.711.67%31.63%10.38%8/14/2025 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-$535.60M-$3.92N/A25.422.11-4.86%-2.02%-1.49%8/7/2025 (Estimated)

Latest ESLOY, CSLLY, VRTX, and GILD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2025Q1 2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billion
4/24/2025Q1 2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.77$1.81+$0.04$1.04$6.77 billion$6.67 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CSL Limited stock logo
CSLLY
CSL
$1.201.51%N/AN/AN/A
EssilorLuxottica Société anonyme stock logo
ESLOY
EssilorLuxottica Société anonyme
$1.611.15%N/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.162.91%+2.74%66.53%10 Years
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest ESLOY, CSLLY, VRTX, and GILD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.793%6/13/20256/13/20256/27/2025
5/6/2025
EssilorLuxottica Société anonyme stock logo
ESLOY
EssilorLuxottica Société anonyme
$1.83301.26%5/12/20255/13/20256/26/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CSL Limited stock logo
CSLLY
CSL
0.58
2.18
0.97
EssilorLuxottica Société anonyme stock logo
ESLOY
EssilorLuxottica Société anonyme
0.13
0.88
0.62
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.24
1.50
1.20
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.01
2.69
2.35

Institutional Ownership

CompanyInstitutional Ownership
CSL Limited stock logo
CSLLY
CSL
0.03%
EssilorLuxottica Société anonyme stock logo
ESLOY
EssilorLuxottica Société anonyme
0.01%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
CSL Limited stock logo
CSLLY
CSL
30,000968.42 millionN/ANot Optionable
EssilorLuxottica Société anonyme stock logo
ESLOY
EssilorLuxottica Société anonyme
190,000915.01 millionN/ANot Optionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
4,800256.80 million256.28 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CSL stock logo

CSL OTCMKTS:CSLLY

$79.57 -1.21 (-1.50%)
As of 03:59 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

EssilorLuxottica Société anonyme stock logo

EssilorLuxottica Société anonyme OTCMKTS:ESLOY

$140.61 -3.11 (-2.17%)
As of 03:59 PM Eastern

EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir, eyexpert, iWear, Humanware, and Optifog brands. It also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the Essilor Instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the Satisloh brand. In addition, the company provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Alain Mikli, Costa, Bliz, Native, Luxottica, Sferoflex, Bolon, Molsion, DbyD, and Unofficial and Seen, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$108.44 -0.65 (-0.60%)
Closing price 04:00 PM Eastern
Extended Trading
$108.49 +0.05 (+0.05%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$445.10 -0.90 (-0.20%)
Closing price 04:00 PM Eastern
Extended Trading
$439.92 -5.18 (-1.16%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.